Dr. Andrea George

Dr. Andrea George arbeitet an der Entwicklung hochgranularer Kalorimeter-Detektoren für zukünftige Teilchenbeschleuniger, insbesondere für lineare Elektron-Positron-Kollider. Sie konzipiert und testet innovative Detektorsysteme mit Resistiven Plattendetektoren (RPCs) und Silizium-Photomultipliern (SiPMs), um Teilchenschauer mit extrem hoher räumlicher Auflösung zu messen und zu rekonstruieren. Die Arbeiten ermöglichen präzisere Messungen von Higgs-Boson-Eigenschaften und anderen Hochenergie-Phänomenen und sind zentral für die nächste Generation von Forschungsinfrastrukturen in der Grundlagenphysik. Parallel koordiniert sie internationale Doktorandenprogramme der Jameel Education Foundation an der Humboldt-Universität.

🔒 Das System hat 193 mögliche Industrie-Partner gefunden — Firmen, Scores und Begründungen sind nur für eingeloggte Nutzer:innen sichtbar. Anmelden

• Jameel 16. Kohorte - Pauschalmittel

  Quelle ↗

  Förderer: Andere internationale Stiftungen Zeitraum: 11/2021 - 05/2028 Projektleitung: Dr. Andrea George

• Jameel Education Foundation - Humboldt-Universität zu Berlin - Scholarship Agreement 16th Cohort

  Quelle ↗

  Förderer: Andere internationale Stiftungen Zeitraum: 11/2021 - 10/2026 Projektleitung: Dr. Andrea George

• Doctoral Scholarships from Jameel Education Foundation 17th Cohort

  Quelle ↗

  Förderer: Andere internationale Stiftungen Zeitraum: 03/2023 - 12/2027 Projektleitung: Dr. Andrea George, Jeannette Latino, apl. Prof. Dr. Sabine Hunke

• The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update

  2018

  Allergy · DOI

  Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: (1) How should HAE-1/2 be defined and classified?, (2) How should HAE-1/2 be diagnosed?, (3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, (4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and (5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures?

• The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

  2022

  Allergy · DOI

  Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.